By transplanting a plant-specific degradation pathway controlled by a phytohormone, auxin, into non-plant cells, researchers at the Japanese National Institutes of Genetics have developed a rapid protein degradation process – the auxin-inducible degron (AID) technology.
The industry's expanding quest for protein degraders grew a little larger on July 9 with Sanofi SA tapping Kymera Therapeutics Inc. to advance two new protein degrader programs, one of which will target IRAK4 in patients with immune-inflammatory diseases and another for an undisclosed target. Each program could yield multiple therapies.
BOSTON – At the AACR-NCI-EORTC Molecular Targets meeting in October, speakers in the second plenary session gave examples both of how far protein degradation has come as a pharmacological approach, and how far it could still go.
